Q-omics provides the consensus-scored SS18L2P1 profile across patient tissues and cancer cell-line models. SS18L2P1 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SS18L2P1 is differentially expressed in 2, with the highest sampling consensus in UCEC. Additionally, SS18L2P1 RNA expression shows 6,247 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SKCM, UCEC, and STAD as cancer lineages where SS18L2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SS18L2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SS18L2P1 survival associations across molecular data types. SS18L2P1 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SS18L2P1 RNA expression–survival associations across cancer types. High SS18L2P1 expression shows unfavorable associations in SKCM, THYM, GBM and LUAD, but favorable associations in COAD and BLCA. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SS18L2P1 RNA expression.
This table summarizes SS18L2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for SS18L2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SS18L2P1 shows higher tumor expression in UCEC and KIRP. The UCEC box plot shows higher SS18L2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.254, t-test p = .005).
This table shows molecular features associated with SS18L2P1 in patient tissues and cancer cell lines. In patient samples, SS18L2P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
